Fallen British Celebrities: Second Opportunity for Investment in Quality Shares

Fallen British Celebrities: Second Opportunity for Investment in Quality Shares

In the past year, a dramatic shift has taken place in the market for high-quality British companies. Once-admired firms, such as Spirax, a specialist steam systems provider, have seen their share prices plummet, with Spirax's shares falling from an all-time high of more than £172 in November 2021 to roughly £60 today. This dramatic shift was triggered by a surge in inflation and aggressively rising interest rates that provided attractive alternatives to equities.

However, this valuation crunch presents both opportunities and risks for investors. While the stocks of these firms are now much cheaper, with a p/e of 20-25, providing a margin of safety compared to the 40-50 times earnings seen at their peaks, private equity (PE) buyouts pose several threats.

Private equity firms, such as Advent International, which recently bought Spectris, a high-tech precision measurement firm, are drawn to these quality businesses that have become not just cheap, but too cheap. The takeover of Spectris is seen as a warning for investors in Britain's most respected companies.

Investors in undervalued, high-quality British companies face several risks from PE buyouts. One of the key risks is the short-term focus and asset stripping that PE firms often employ. They tend to cut costs aggressively by laying off staff, squeezing suppliers, and selling assets, which can undermine the company’s sustainable value and operational health.

Reduced investment and innovation can also be a concern. Cost-cutting and operational centralization can lead to underinvestment in the company’s core capabilities and infrastructure, harming innovation and customer service quality. This degradation can reduce the company’s competitive edge over time.

PE buyouts often increase leverage on the acquired company’s balance sheet, heightening financial risk. This can make the firm more vulnerable to economic downturns or operational challenges, negatively impacting investor returns.

Potential erosion of shareholder value is another risk. While undervalued companies may seem attractive targets, the early exit strategies and cost pressures from PE owners might hamper the company’s ability to realize its intrinsic value, limiting capital appreciation opportunities for investors.

In the broader UK corporate context, early pension scheme buyouts or restructuring encouraged by PE involvement could cause firms to miss out on surplus values, representing a loss to shareholder wealth.

Despite these risks, the core appeal of high-quality British businesses remains due to their dominant positions in niche, global markets, high returns on capital employed (ROCE), and prodigious cash flow. Many of these firms are plugged into unstoppable long-term trends, such as the drive for greater energy efficiency and factory automation.

For instance, Tristel, a manufacturer of infection prevention products, secured FDA approval, opening up a market that could potentially double its sales over the long term, providing a tangible catalyst for growth.

Many firms are taking action to improve efficiency and manage costs, such as Treatt implementing self-help measures. This patience and focus on fundamentals may pay off in the long run, as the re-rating of these businesses will not happen overnight.

However, the low valuations afflicting Britain's quality companies do not just represent a potential opportunity for new investors; they also represent an existential threat, as they may be acquired and taken private, lost to public shareholders forever. Investors must weigh these risks carefully before diving into the market for undervalued British companies.

References:

1. PE-backed deals could drain £100bn from UK pension pots - FT Advisor
2. The Risks and Rewards of Private Equity Investing
3. Private Equity and the British Economy
4. The Impact of Private Equity on Innovation
5. The dramatic drop in share prices of high-quality British companies, such as Spirax, has created a margin of safety due to their low p/e ratios, but private-equity (PE) buyouts pose several risks for investors, including a short-term focus, asset stripping, reduced investment and innovation, increased financial risk, potential erosion of shareholder value, and loss of surplus values from early pension scheme buyouts or restructuring.
6. PE firms, like Advent International, which recently bought Spectris, are attracted to the undervalued, high-quality British companies, but their strategies can lead to cost-cutting, operational centralization, layoffs, asset sales, increased leverage, and early exit strategies that may harm the company's sustainable value, operational health, and long-term growth opportunities.
7. Despite these risks, the core appeal of high-quality British businesses lies in their dominant positions in niche, global markets, high returns on capital employed (ROCE), and prodigious cash flow. Companies like Tristel, which secured FDA approval, and Treatt, which implemented self-help measures, are taking action to improve efficiency and manage costs to capitalize on long-term trends, such as increased demand for infection prevention products and factory automation.
8. The low valuations afflicting Britain's quality companies do not only present a potential opportunity for new investors; they also represent a threat, as they may be acquired and taken private, lost to public shareholders forever. To mitigate these risks, investors must weigh the benefits of investing in undervalued British companies against the potential downsides, such as the strategic decisions made by PE firms and the impact on the firms' long-term growth prospects.

Read also: